ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer’s Disease Clinical trials evaluating PMN310 expected to initiate in 2019 TORONTO, Ontario and Cambridge, Massachusetts – September 19, 2017 –…
ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease TORONTO, Ontario and Cambridge, Massachusetts – Sept. 13, 2017 – ProMIS Neurosciences, Inc., a company focused on…
ProMIS Neurosciences Completes Second Closing of Private Placement TORONTO, ONTARIO – August 28, 2017 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN; OTCPK:ARFX.F; DB:23J) is pleased to announce that, further to its news releases dated July 20, 2017, August…
ProMISTM Neurosciences, Inc. NEWS RELEASE TSX: PMN FOR IMMEDIATE RELEASE ProMIS Neurosciences Announces Second Quarter 2017 Results TORONTO, ONTARIO and CAMBRIDGE, MA –August 11, 2017 – ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”), a company focused on the discovery and…
ProMIS Neurosciences Completes First Closing of Private Placement /NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, ONTARIO – August 9, 2017 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN; OTCPK:ARFX.F; DB:23J) is…
ProMIS Neurosciences Increases Size of Private Placement to $6 Million /NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, ONTARIO – August 2, 2017 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN; OTCPK:ARFX.F;…